A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in lung cancer cells
This study identifies gorilla-derived adenovirus GRAd32 as a naturally lung cancer-selective oncolytic vector, which was further optimized into a chimeric GRAd32Fk25 platform with enhanced infectivity and the ability to express therapeutic anti-HER3 antibodies while maintaining safety in normal cells.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment has long relied on the idea of attacking a tumor with a weapon that leaves healthy tissue unharmed. One promising approach involves using viruses, which are naturally good at infecting cells, but are engineered or selected to target only cancer cells. These "oncolytic" viruses work by sneaking into a tumor, multiplying inside it, and bursting the cell open to kill it. This destruction does more than just remove the infected cell; it also alerts the body's immune system to the presence of the cancer, potentially helping the immune system find and attack other parts of the tumor. For decades, scientists have mostly used viruses derived from the common human adenovirus, a type of virus that causes mild respiratory infections. However, because so many people have already been exposed to this human virus, their immune systems often recognize and destroy the treatment before it can reach the tumor. This has led researchers to look for viruses from other animals that might be invisible to human immune defenses and behave differently inside our bodies.
A team of researchers from Italy has turned their attention to a group of viruses found in gorillas. They discovered that these gorilla viruses fall into two distinct families with very different behaviors. One family, which they call Group B, acts much like the human virus: it infects and multiplies in both cancer cells and healthy cells. The other family, Group C, contains a specific virus, GRAd32, that behaves in a surprisingly selective way. This virus enters certain lung cancer cells and multiplies rapidly, destroying them, but it hits a dead end when it tries to enter healthy lung cells, failing to replicate and causing no harm. This natural ability to distinguish between sick and healthy tissue is rare and highly valuable, as it removes the need for complex genetic modifications that often weaken other viruses.
To make this selective virus even more effective, the scientists wanted to broaden its reach. While GRAd32 was excellent at killing some types of lung cancer, it struggled to infect other cancer cell lines. The researchers suspected this was because the virus used a specific "key" on its surface, called a fiber knob, to unlock the door to the cell, and that key did not fit all the locks found on different cancer cells. They decided to swap this key. They took the fiber knob from the less selective Group B virus and attached it to the body of the selective Group C virus. The result was a new, hybrid virus. This chimera could enter a wider variety of cancer cells, including those the original virus could not touch, while still refusing to multiply in healthy cells. The modification successfully expanded the virus's ability to find and destroy tumors without losing its safety profile.
The researchers then took this hybrid virus one step further, turning it into a factory for a powerful cancer-fighting drug. They inserted the genetic instructions for a specific antibody, a protein designed to block a receptor called HER3 that helps many tumors grow and resist treatment. Normally, doctors must inject these antibodies into a patient's bloodstream, where they circulate everywhere, potentially causing side effects. By putting the instructions inside the virus, the scientists ensured that the antibody would only be produced inside the cancer cells that the virus infected. When the virus entered a tumor cell, it began to churn out this antibody, which then worked locally to shut down the cancer's growth signals. The team confirmed that the antibody produced by the virus was fully functional, capable of binding to its target and stopping the chemical pathways that tumors use to survive.
This work suggests a new path forward for cancer therapy. The researchers found that the gorilla virus not only kills cells directly but also delivers a targeted drug exactly where it is needed, all while avoiding the healthy tissues that usually suffer from side effects. They also noted that because this virus comes from a gorilla, it is unlikely that most people have pre-existing immunity against it, which could allow it to be delivered through the bloodstream more easily than current treatments. While the study was conducted in cell cultures and not yet in patients, the findings demonstrate that these gorilla viruses are a versatile platform. They offer a way to combine the direct killing power of a virus with the precision of modern antibody therapy, creating a dual-action weapon that is naturally selective and potentially safer for systemic use.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.